CEACAM5 and squamous cell carcinoma: Serum biomarkers employed in the current clinical setting such as ENO (enolase alpha), CEA (carcinoembryonic antigen), SCC (squamous cell carcinoma), CA-125 (cancer antigen 125) or TPA (tissue polypeptide antigen) are not satisfactory due to their low sensitivity and specificity [13,14].